Author:
Vázquez Luis A.,Tofé-Povedano Santiago,Bellido-Guerrero Diego,Botella-Serrano Marta,Soto-González Alfonso,Mezquita-Raya Pedro,Delgado Elías,Fajardo-Montañana Carmen,Morales-Portillo Cristóbal,Causanilles Ana,Rubio-de Santos Miriam,Romera Irene,Jódar-Gimeno Esteban
Publisher
Springer Science and Business Media LLC
Reference54 articles.
1. European Medicines Agency. Mounjaro: EPAR – Product information. https://www.ema.europa.eu/en/documents/product-information/mounjaro-epar-product-information_en.pdf. Accessed 26 Jan 2023
2. Chavda VP, Ajabiya J, Teli D, Bojarska J, Apostolopoulos V. Tirzepatide, a new era of dual-targeted treatment for diabetes and obesity: a mini-review. Molecules [Internet]. 2022;27(13):4315.
3. Thomas MK, Nikooienejad A, Bray R, Cui X, Wilson J, Duffin K, et al. Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes. J Clin Endocrinol Metab. 2021;106(2):388–96.
4. Rosenstock J, Wysham C, Frías JP, Kaneko S, Lee CJ, Fernández Landó L, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398(10295):143–55.
5. Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503–15.